BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21363912)

  • 1. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.
    Hill VK; Ricketts C; Bieche I; Vacher S; Gentle D; Lewis C; Maher ER; Latif F
    Cancer Res; 2011 Apr; 71(8):2988-99. PubMed ID: 21363912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
    Fackler MJ; Umbricht CB; Williams D; Argani P; Cruz LA; Merino VF; Teo WW; Zhang Z; Huang P; Visvananthan K; Marks J; Ethier S; Gray JW; Wolff AC; Cope LM; Sukumar S
    Cancer Res; 2011 Oct; 71(19):6195-207. PubMed ID: 21825015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.
    Lapidus RG; Ferguson AT; Ottaviano YL; Parl FF; Smith HS; Weitzman SA; Baylin SB; Issa JP; Davidson NE
    Clin Cancer Res; 1996 May; 2(5):805-10. PubMed ID: 9816234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
    Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
    BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
    Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
    Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer.
    Li L; Lee KM; Han W; Choi JY; Lee JY; Kang GH; Park SK; Noh DY; Yoo KY; Kang D
    Hum Mol Genet; 2010 Nov; 19(21):4273-7. PubMed ID: 20724461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
    Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
    Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
    Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes.
    Zhang M; Zhang S; Wen Y; Wang Y; Wei Y; Liu H; Zhang D; Su J; Wang F; Zhang Y
    PLoS One; 2015; 10(11):e0142279. PubMed ID: 26550991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
    Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation signature of lymph node metastases in breast cancer patients.
    Barekati Z; Radpour R; Lu Q; Bitzer J; Zheng H; Toniolo P; Lenner P; Zhong XY
    BMC Cancer; 2012 Jun; 12():244. PubMed ID: 22695536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.
    Conway K; Edmiston SN; Tse CK; Bryant C; Kuan PF; Hair BY; Parrish EA; May R; Swift-Scanlan T
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):921-30. PubMed ID: 25809865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing.
    Sun Z; Asmann YW; Kalari KR; Bot B; Eckel-Passow JE; Baker TR; Carr JM; Khrebtukova I; Luo S; Zhang L; Schroth GP; Perez EA; Thompson EA
    PLoS One; 2011 Feb; 6(2):e17490. PubMed ID: 21364760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype.
    Chen XQ; Zhang F; Su QC; Zeng C; Xiao FH; Peng Y
    Clin Epigenetics; 2020 Jan; 12(1):16. PubMed ID: 31959227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation and hormone receptor status in breast cancer.
    Benevolenskaya EV; Islam AB; Ahsan H; Kibriya MG; Jasmine F; Wolff B; Al-Alem U; Wiley E; Kajdacsy-Balla A; Macias V; Rauscher GH
    Clin Epigenetics; 2016; 8():17. PubMed ID: 26884818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry.
    Ambrosone CB; Young AC; Sucheston LE; Wang D; Yan L; Liu S; Tang L; Hu Q; Freudenheim JL; Shields PG; Morrison CD; Demissie K; Higgins MJ
    Oncotarget; 2014 Jan; 5(1):237-48. PubMed ID: 24368439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers.
    de Almeida BP; Apolónio JD; Binnie A; Castelo-Branco P
    BMC Cancer; 2019 Mar; 19(1):219. PubMed ID: 30866861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
    Xu J; Shetty PB; Feng W; Chenault C; Bast RC; Issa JP; Hilsenbeck SG; Yu Y
    BMC Cancer; 2012 Jun; 12():243. PubMed ID: 22695491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
    Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.